TY - JOUR
T1 - MicroRNA-383
T2 - A tumor suppressor miRNA in human cancer
AU - Jafarzadeh, Abdollah
AU - Noori, Majid
AU - Sarrafzadeh, Shaghayegh
AU - Tamehri Zadeh, Seyed Saeed
AU - Nemati, Maryam
AU - Chatrabnous, Nazanin
AU - Jafarzadeh, Sara
AU - Hamblin, Michael R.
AU - Jafari Najaf Abadi, Mohammad Hassan
AU - Mirzaei, Hamed
N1 - Publisher Copyright:
Copyright © 2022 Jafarzadeh, Noori, Sarrafzadeh, Tamehri Zadeh, Nemati, Chatrabnous, Jafarzadeh, Hamblin, Jafari Najaf Abadi and Mirzaei.
PY - 2022/10/13
Y1 - 2022/10/13
N2 - Downregulated expression of anti-tumor miR-383 has been found in many kinds of cancer. MiR-383 family members can directly target the 3′-untranslated region (3′-UTR) of the mRNA of some pro-tumor genes to attenuate several cancer-related processes, including cell proliferation, invasion, migration, angiogenesis, immunosuppression, epithelial-mesenchymal transition, glycolysis, chemoresistance, and the development of cancer stem cells, whilst promoting apoptosis. Functionally, miR-383 operates as a tumor inhibitor miRNA in many types of cancer, including breast cancer, hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, esophageal cancer, lung cancer, head and neck cancer, glioma, medulloblastoma, melanoma, prostate cancer, cervical cancer, oral squamous cell carcinoma, thyroid cancer, and B-cell lymphoma. Both pro-tumor and anti-tumor effects have been attributed to miR-383 in ovarian cancer. However, only the pro-tumor effects of miR-383 were reported in cholangiocarcinoma. The restoration of miR-383 expression could be considered a possible treatment for cancer. This review discusses the anti-tumor effects of miR-383 in human cancers, emphasizing their downstream target genes and potential treatment approaches.
AB - Downregulated expression of anti-tumor miR-383 has been found in many kinds of cancer. MiR-383 family members can directly target the 3′-untranslated region (3′-UTR) of the mRNA of some pro-tumor genes to attenuate several cancer-related processes, including cell proliferation, invasion, migration, angiogenesis, immunosuppression, epithelial-mesenchymal transition, glycolysis, chemoresistance, and the development of cancer stem cells, whilst promoting apoptosis. Functionally, miR-383 operates as a tumor inhibitor miRNA in many types of cancer, including breast cancer, hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, esophageal cancer, lung cancer, head and neck cancer, glioma, medulloblastoma, melanoma, prostate cancer, cervical cancer, oral squamous cell carcinoma, thyroid cancer, and B-cell lymphoma. Both pro-tumor and anti-tumor effects have been attributed to miR-383 in ovarian cancer. However, only the pro-tumor effects of miR-383 were reported in cholangiocarcinoma. The restoration of miR-383 expression could be considered a possible treatment for cancer. This review discusses the anti-tumor effects of miR-383 in human cancers, emphasizing their downstream target genes and potential treatment approaches.
KW - cancer
KW - miR-383
KW - miR-383-3p
KW - mir-383-5p
KW - target genes
UR - http://www.scopus.com/inward/record.url?scp=85141082008&partnerID=8YFLogxK
U2 - 10.3389/fcell.2022.955486
DO - 10.3389/fcell.2022.955486
M3 - Review article
AN - SCOPUS:85141082008
SN - 2296-634X
VL - 10
JO - Frontiers in Cell and Developmental Biology
JF - Frontiers in Cell and Developmental Biology
M1 - 955486
ER -
